Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion

NCT01752920 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT01752920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01752920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 1/2
Overall status
Completed
Start date
December 10, 2012
Completion date
August 28, 2018
Enrollment
119 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor